Literature DB >> 28256296

Prediction of functional recovery after percutaneous coronary revascularization for chronic total occlusion using late gadolinium enhanced magnetic resonance imaging.

Tatsuya Nakachi1, Shingo Kato2, Hidekuni Kirigaya2, Naoki Iinuma2, Kazuki Fukui2, Naka Saito2, Tae Iwasawa3, Masami Kosuge4, Kazuo Kimura4, Kouichi Tamura5.   

Abstract

BACKGROUND: Limited data are available regarding the prediction for functional recovery using late gadolinium enhanced magnetic resonance imaging (LGE MRI) after coronary revascularization for chronic total occlusion (CTO PCI).
METHODS: We studied 59 patients (mean age, 66±11 years) who underwent successful CTO PCI. Two-dimensional echocardiography and strain measurements were performed before and 8±2 months after CTO PCI. The findings of segmental assessment were compared with the extent of LGE MRI using a 16-segment model.
RESULTS: From baseline to follow-up, ejection fraction (54.2±12.1% to 56.1±10.6%, p=0.010), global longitudinal strain (LS) (-15.1±5.1 to -16.7±5.1, p<0.001), global circumferential strain (CS) (-14.0±4.9 to -15.9±4.9, p<0.001), and wall motion score (WMS) index (1.45±0.53 to 1.33±0.39, p=0.014) significantly improved. In the territory of the CTO vessel, LS and CS significantly improved in segments of LGE ≤50%, but not in segments of LGE >50%. However, WMS improved only in segments of LGE 1-25%. At baseline and at follow-up, CS allowed better discrimination of segments of LGE >50% than WMS [at baseline; area under the curve (AUC) 0.79 vs. 0.68, respectively, p=0.001: at follow-up; AUC 0.84 vs. 0.69, respectively, p<0.001). Discriminatory ability of LS for segments of LGE >50% significantly improved from baseline to follow-up (AUC 0.73 vs. 0.83, p<0.001).
CONCLUSIONS: The cut-off value of the extent of LGE MRI is 50% to detect segments that will functionally recover after CTO PCI. Change in LS was more sensitive for removal of ischemia by CTO PCI, indicating the utility of LS to monitor the therapeutic effects of CTO recanalization.
Copyright © 2017 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chronic total occlusion; Late gadolinium enhancement; Magnetic resonance imaging; Percutaneous coronary intervention; Two-dimensional speckle tracking echocardiography

Mesh:

Substances:

Year:  2017        PMID: 28256296     DOI: 10.1016/j.jjcc.2017.01.002

Source DB:  PubMed          Journal:  J Cardiol        ISSN: 0914-5087            Impact factor:   3.159


  4 in total

Review 1.  The Role of Multimodality Imaging for Percutaneous Coronary Intervention in Patients With Chronic Total Occlusions.

Authors:  Eleonora Melotti; Marta Belmonte; Carlo Gigante; Vincenzo Mallia; Saima Mushtaq; Edoardo Conte; Danilo Neglia; Gianluca Pontone; Carlos Collet; Jeroen Sonck; Luca Grancini; Antonio L Bartorelli; Daniele Andreini
Journal:  Front Cardiovasc Med       Date:  2022-05-02

Review 2.  The indications and utility of adjunctive imaging modalities for chronic total occlusion (CTO) intervention.

Authors:  Usaid K Allahwala; Emmanouil S Brilakis; Hosen Kiat; Sally Ayesa; Daniel Nour; Michael Ward; Sidney Lo; James C Weaver; Ravinay Bhindi
Journal:  J Nucl Cardiol       Date:  2020-10-06       Impact factor: 5.952

3.  Role of Myocardial Extracellular Volume Fraction Measured with Magnetic Resonance Imaging in the Prediction of Left Ventricular Functional Outcome after Revascularization of Chronic Total Occlusion of Coronary Arteries.

Authors:  Yinyin Chen; Xinde Zheng; Hang Jin; Shengming Deng; Daoyuan Ren; Andreas Greiser; Caixia Fu; Hongxiang Gao; Mengsu Zeng
Journal:  Korean J Radiol       Date:  2018-12-27       Impact factor: 3.500

4.  Scoring System for Identification of "Survival Advantage" after Successful Percutaneous Coronary Intervention in Patients with Chronic Total Occlusion.

Authors:  Tatsuya Nakachi; Shun Kohsaka; Masahisa Yamane; Toshiya Muramatsu; Atsunori Okamura; Yoshifumi Kashima; Shunsuke Matsuno; Masami Sakurada; Yoshitane Seino; Maoto Habara
Journal:  J Clin Med       Date:  2020-05-02       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.